Literature DB >> 28125840

Association of High-Mobility Group Box-1 With Th Cell-Related Cytokines in the Vitreous of Ocular Sarcoidosis Patients.

Masaru Takeuchi1, Manzo Taguchi1, Tomohito Sato1, Kyoko Karasawa1, Yutaka Sakurai1, Kohzou Harimoto1, Masataka Ito2.   

Abstract

Purpose: High-mobility group box-1 (HMGB1) is a nonhistone DNA-binding nuclear protein released from necrotic cells, which is also secreted by activated leukocytes and acts as a primary proinflammatory cytokine. In this study, we compared vitreous HMGB1 levels in ocular sarcoidosis with those in noninflammatory vitreoretinal diseases and evaluated its association with Th cell-related and proinflammatory cytokines.
Methods: The study group consisted of 24 patients with ocular sarcoidosis. The control group consisted of 27 patients with proliferative diabetic retinopathy (PDR) and 24 with idiopathic epiretinal membrane (ERM). Vitreous fluid samples were obtained at the beginning of vitrectomy. Vitreous levels of HMGB1 and IL-1β, IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, IFN-γ, soluble CD40 ligand (sCD40L), and TNFα were measured.
Results: High-mobility group box-1 was detected in the vitreous of 23 of 24 patients (95.8%) with ocular sarcoidosis. Mean vitreous level of HMGB1 was the highest in the sarcoidosis group, followed by the PDR and ERM groups, with significant differences between the three groups. In the sarcoidosis group, vitreous levels of IL-6, IL-10, IL-31, IFN-γ, sCD40L, and TNFα were significantly higher than those in the idiopathic ERM group, and IFN-γ and sCD40L were significantly higher than those in the PDR group. Vitreous HMGB-1 level correlated significantly with IL-10, IFN-γ, and sCD40L levels but not with IL-6, IL-17, IL-31, or TNFα levels. Conclusions: The vitreous level of HMGB1 is elevated in ocular sarcoidosis and is associated with vitreous levels of Th1- and regulatory T-related cytokines, but not with proinflammatory or Th17-related cytokines.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28125840     DOI: 10.1167/iovs.16-20324

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

Review 1.  Ocular sarcoidosis: new diagnostic modalities and treatment.

Authors:  Sung J Yang; Sherveen Salek; James T Rosenbaum
Journal:  Curr Opin Pulm Med       Date:  2017-09       Impact factor: 3.155

2.  HIMF (Hypoxia-Induced Mitogenic Factor) Signaling Mediates the HMGB1 (High Mobility Group Box 1)-Dependent Endothelial and Smooth Muscle Cell Crosstalk in Pulmonary Hypertension.

Authors:  Qing Lin; Chunling Fan; Jose Gomez-Arroyo; Katrien Van Raemdonck; Lucas W Meuchel; John T Skinner; Allen D Everett; Xia Fang; Andrew A Macdonald; Kazuyo Yamaji-Kegan; Roger A Johns
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-10-10       Impact factor: 8.311

Review 3.  Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis.

Authors:  Ryan H Mason; Samuel A Minaker; Gabriela Lahaie Luna; Priya Bapat; Armin Farahvash; Anubhav Garg; Nishaant Bhambra; Rajeev H Muni
Journal:  Eye (Lond)       Date:  2022-06-07       Impact factor: 4.456

4.  Damage-associated Molecular Patterns in Clinical and Animal Models of Uveitis.

Authors:  Henry J Kaplan; Deming Sun; Hui Shao
Journal:  Ocul Immunol Inflamm       Date:  2021-09-03       Impact factor: 3.728

Review 5.  Interleukins and cytokine biomarkers in uveitis.

Authors:  S Balamurugan; Dipankar Das; Murat Hasanreisoglu; Brian C Toy; Mashal Akhter; V K Anuradha; Eliza Anthony; Bharat Gurnani; Kirandeep Kaur
Journal:  Indian J Ophthalmol       Date:  2020-09       Impact factor: 1.848

6.  Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept.

Authors:  Tomohito Sato; Toshio Enoki; Yoko Karasawa; Hideaki Someya; Manzo Taguchi; Kozo Harimoto; Kei Takayama; Takayuki Kanda; Masataka Ito; Masaru Takeuchi
Journal:  Front Immunol       Date:  2021-10-13       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.